Risperidone Long-acting Injection Generics - Manufacturers & Suppliers
Risperdal Consta(US &EU)
| Product/Composition:- | Risperidone Long-Acting Injection |
|---|---|
| Strength:- | 12.5 mg, 25 mg, 37.5 mg, 50 mg vials/syringes |
| Form:- | Long-Acting Injection |
| Reference Brands:- | Risperdal Consta(US &EU) |
| MOQ | As per the manufacturer batch size |
| Get Quote Send Enquiry on WhatsApp | |
Risperidone LAI is a long-acting antipsychotic injection used biweekly to treat schizophrenia and bipolar disorder. Marketed as Risperdal Consta, it ensures consistent medication delivery and enhances adherence. Approved in the US and EU, it plays a vital role in long-term psychiatric management with ongoing interest in generic alternatives.
Risperidone Long-Acting Injection, commonly marketed as Risperdal Consta, is a second-generation antipsychotic approved in both the US (FDA) and EU (EMA) for the treatment of schizophrenia and maintenance therapy in bipolar disorder. It is administered intramuscularly every two weeks and provides steady plasma levels, improving adherence in patients with chronic psychosis. The drug requires prior oral risperidone trial before initiating long-acting therapy. In the EU, it is approved under centralized and national procedures. In the US, it holds FDA approval under NDA. Its prolonged-release formulation is protected by a series of patents, though generic development has begun in select markets.